1. The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis

   • Eric Jutkowitz
   • Fernando Alarid-Escudero
   • Hawre Jalal

   Practical Application 14 February 2019 Pages: 871 - 877

   

2. Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Xavier Armoiry
   • Ewen Cummins
   • Hema Mistry

   Review Article 14 November 2018 Pages: 879 - 886

3. Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Bram L. T. Ramaekers
   • Rob Riemsma
   • Manuela A. Joore

   Review Article Open access 14 November 2018 Pages: 887 - 894

4. A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective

   • Steve Ryder
   • Kathleen Fox
   • Jos Kleijnen

   Systematic Review 04 April 2019 Pages: 895 - 919

   

5. Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation

   • Hui Shao
   • Shuang Yang
   • Lizheng Shi

   Original Research Article 19 February 2019 Pages: 921 - 929

6. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients

   • Michelle Tew
   • Philip Clarke
   • Kim Dalziel

   Original Research Article 13 March 2019 Pages: 931 - 941

   

7. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease

   • Yawen Jiang
   • Weiyi Ni

   Original Research Article 14 March 2019 Pages: 943 - 952

   

8. The Cancer Drugs Fund in Practice and Under the New Framework

   • Celia Sabry-Grant
   • Kinga Malottki
   • Alexander Diamantopoulos

   Original Research 03 April 2019 Pages: 953 - 962

   

9. Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

   • R. Brett McQueen
   • Melanie D. Whittington
   • Jonathan D. Campbell

   Letter to the Editor 02 May 2019 Pages: 963 - 964

10. Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’

    • Holly Guy
    • Lydia Walder
    • Mark Fisher

    Letter to the Editor 02 May 2019 Pages: 965 - 967

    

11. Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?

    • Paul Mark Mitchell
    • Sridhar Venkatapuram
    • Joanna Coast

    Correction Open access 09 March 2019 Pages: 969 - 969

12. Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial

    • Baptiste Leurent
    • Manuel Gomes
    • James R. Carpenter

    Correction Open access 09 March 2019 Pages: 971 - 971

13. Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities

    • Edna Keeney
    • Dalia Dawoud
    • Sofia Dias

    Correction Open access 09 March 2019 Pages: 973 - 973